Pharming Group NV, a specialty pharmaceutical company headquartered in Leiden, Netherlands, is poised to release its latest quarterly financial results on November 5, 2026. The company, which operates within the biotechnology sector of the health care industry, is known for its focus on developing and producing human therapeutic proteins aimed at addressing rare diseases and unmet medical needs.
As of October 20, 2026, Pharming Group NV’s close price stood at 0.851 EUR, with a 52-week high of 1.818 EUR recorded on January 27, 2026, and a 52-week low of 0.82 EUR on October 18, 2026. The company’s market capitalization is valued at approximately 595.24 million EUR. Despite a high price-to-earnings ratio of 74.35, analysts are optimistic about the company’s financial performance in the upcoming quarterly report.
Pharming Group NV’s lead product, Ruconest, is a recombinant human C1 esterase inhibitor used for treating angioedema attacks in patients with acute hereditary angioedema (HAE). This product is available in several regions, including Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein. Additionally, the company is advancing the development of recombinant human C1 inhibitor for HAE attacks and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A.
Strategic collaborations play a significant role in Pharming Group NV’s operations. The company has partnered with the Shanghai Institute of Pharmaceutical Industry to develop, manufacture, and commercialize new products based on its Pharming technology platform. Furthermore, a partnership agreement with the China State Institute of Pharmaceutical Industry focuses on the development of rhFVIII for the treatment of haemophilia A.
Analysts anticipate a modest rise in earnings per share for Pharming Group NV compared to the previous year, along with a small but positive increase in revenue. The overall financial outlook for the current fiscal year is expected to improve, with projections indicating higher earnings relative to the prior year. This positive market sentiment reflects the belief that Pharming Group is maintaining a steady growth trajectory in both profitability and sales.
Pharming Group NV’s American Depositary Shares (REPR 10) are listed on the NYSE Euronext Amsterdam, and the company’s financial performance will be closely monitored by investors and industry analysts following the release of its quarterly results.
